Skip to main content

Drug Interactions between etodolac and Novavax COVID-19 (2023-2024) Vaccine,Adjuvanted PF (cvx 313)

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between etodolac and Novavax COVID-19 (2023-2024) Vaccine,Adjuvanted PF (cvx 313). However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

etodolac

A total of 381 drugs are known to interact with etodolac.

Novavax COVID-19 (2023-2024) Vaccine,Adjuvanted PF (cvx 313)

A total of 343 drugs are known to interact with Novavax COVID-19 (2023-2024) Vaccine,Adjuvanted PF (cvx 313).

  • Novavax covid-19 (2023-2024) vaccine,adjuvanted pf (cvx 313) is in the drug class viral vaccines.
  • Novavax covid-19 (2023-2024) vaccine,adjuvanted pf (cvx 313) is used to treat COVID-19.

Drug and food interactions

Moderate

etodolac food

Applies to: etodolac

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References (1)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer